Ormeloxifene information from DrugsUpdate
L - Contraindicated in lactation
Ormeloxifene (also known as Centchroman) is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a non-hormonal, non-steroidal oral contraceptive which is taken once per week. In India, ormeloxifene has been available as birth control since the early 1990s, and it is currently marketed there under the trade name Saheli. Ormeloxifene has also been licensed under the trade names Centron and Sevista.
Information Not Available
Ormeloxifene acts on oestrogen receptors. It has a weak estrogenic and potent antiestrogenic actions. It is expected to exert a contraceptive effect and normalise the bleeding from uterine cavity by regularising the expression of oestrogen receptors on the endometrium. As a contraceptive, it prevents proliferation and decidualisation of the endometrium, enhances blastocyst formation and slightly increases embryo transport through the oviducts.
Well absorbed from the GI tract. Peak serum levels achieved in 4 hours.
Widely distributed in tissues. Little affinity to plasma proteins.
Terminal half-life: Approx 170 hours.
Women who desire to be pregnant should discontinue taking the drug.
Dysfunctional uterine bleeding
Adult: 60 mg twice a week for the 1st 12 weeks and then 60 mg once a week for up to next 12 weeks.
Adult: Take 1 tablet (30 mg) twice a week for the 1st 12 weeks then 1 tablet (30 mg) once a week from 13th weeks onwards. Take 1st tablet on the 1st day of menstrual cycle. Follow dose irrespective of menstrual periods.
List of Contraindications
Contraindicated in pregnancy
Contraindicated in lactation
Polycystic ovarian disease, cervical hyperplasia, recent history of jaundice or hepatic impairment, severe allergic states, TB, renal impairment. Pregnancy and lactation.